Drug Profile
Research programme: cannabinoid receptor modulators - GW Pharmaceuticals
Alternative Names: Cannabigerol - GW Pharmaceuticals; CBG - GW PharmaceuticalsLatest Information Update: 07 May 2021
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Developer GW Pharmaceuticals; Otsuka Pharmaceutical; University of Reading
- Class Antiepileptic drugs; Antineoplastics; Behavioural disorder therapies; Cannabinoids; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cachexia; Epilepsy; Pancreatic cancer; Pervasive child development disorders